A022101 NRG-GI009

Alliance/NRG Joint Study: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, & Surgery (ERASur)

Principal Investigator

Kathryn Hitchcock, MD

Status

Disease Site

Gastrointestinal [GI] Colorectal

Phase

III

Developmental Therapeutics

No

Primary Objective

To evaluate and compare overall survival (OS) (measured from time of randomization) in patients with newly diagnosed oligometastatic colorectal cancer (oCRC) treated with total ablative therapy (TAT) in addition to standard of care (SOC) systemic therapy versus SOC systemic therapy.

Patient Population: Patients with metastatic colorectal cancer.

Alliance Study Chair: Eric D. Miller, MD, PhD

NRG Study Champions: Kate Hitchcock, MD & Paul Romesser, MD

Patient Population

Patients with metastatic colorectal cancer.

Target Accrual

364